Edition:
India

Array BioPharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

46.64USD
12:20am IST
Change (% chg)

$0.38 (+0.82%)
Prev Close
$46.26
Open
$46.33
Day's High
$46.68
Day's Low
$46.26
Volume
788,208
Avg. Vol
1,173,211
52-wk High
$47.01
52-wk Low
$12.58

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its... (more)

Overall

Beta: 1.64
Market Cap(Mil.): $10,258.19
Shares Outstanding(Mil.): 221.75
Dividend: --
Yield (%): --

Financials

PRESS DIGEST - Wall Street Journal - June 18

June 18 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

18 Jun 2019

Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

18 Jun 2019

Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

18 Jun 2019

US STOCKS-Faith in the Fed nudges Wall Street higher

* Indexes end higher: Dow 0.09%, S&P 500 0.09%, Nasdaq 0.62% (Updated to close)

18 Jun 2019

US STOCKS-Faith in the Fed pushes Wall Street higher

* Indexes up: Dow 0.17%, S&P 500 0.23%, Nasdaq 0.79% (Updated to afternoon)

18 Jun 2019

US STOCKS-Wall Street moves higher; Fed policy meeting on the horizon

* Indexes up: Dow 0.05%, S&P 0.20%, Nasdaq 0.72% (Updates to open)

17 Jun 2019

Pfizer to buy Array for $10.64 bln

June 17 Pfizer Inc said on Monday it had agreed to acquire Array Biopharma Inc for $10.64 billion, which will grant it access to its cancer drugs.

17 Jun 2019

Array BioPharma's colorectal cancer combo treatment meets main goals

Array BioPharma Inc's cocktail of three therapies helped patients with a type of colorectal cancer live longer than those on standard treatment, according to interim results of a late-stage study on Tuesday.

21 May 2019

Array BioPharma's colorectal cancer combo treatment meets main goals

May 21 Array BioPharma Inc's cocktail of three therapies helped patients with a type of colorectal cancer live longer than those on standard treatment, according to interim results of a late-stage study on Tuesday.

21 May 2019

Earnings vs. Estimates